[HTML][HTML] Therapeutic monoclonal antibodies targeting immune checkpoints for the treatment of solid tumors

N Gravbrot, K Gilbert-Gard, P Mehta, Y Ghotmi… - Antibodies, 2019 - mdpi.com
Recently, modulation of immune checkpoints has risen to prominence as a means to treat a
number of solid malignancies, given the durable response seen in many patients and …

[HTML][HTML] The ROP16III-dependent early immune response determines the subacute CNS immune response and type III Toxoplasma gondii survival

…, JA Kochanowsky, A Bhaskara, Y Ghotmi… - PLoS …, 2019 - journals.plos.org
Toxoplasma gondii is an intracellular parasite that persistently infects the CNS and that has
genetically distinct strains which provoke different acute immune responses. How differences …

Targeting glioblastoma using a novel peptide specific to a deglycosylated isoform of brevican

…, CM Fadzen, N Hartrampf, Y Ghotmi… - Advanced …, 2021 - Wiley Online Library
Glioblastoma (GBM) is the most common and deadliest form of brain tumor and remains
amongst the most difficult cancers to treat. Brevican (Bcan), a central nervous system (CNS)‐…

DDIS-36. BTP-7, A NOVEL PEPTIDE FOR THERAPEUTIC TARGETING OF MALIGNANT BRAIN TUMORS

N von Spreckelsen, Y Ghotmi, C Fadzen… - Neuro …, 2019 - academic.oup.com
Glioblastoma (GBM) is one of the most lethal human tumors, and despite considerable advances
in multimodality treatments consisting of surgical removal, radiation and chemotherapy, …

DDIS-19. Novel Peptide Homing to Glioma-Specific Isoform of Brevican Selectively Targets Malignant Brain Tumors

CF Cho, Y Ghotmi, C Fazden, J Wolfe, F Bononi… - Neuro …, 2017 - ncbi.nlm.nih.gov
High-grade gliomas are deadly cancers, and current standard-of-care has demonstrated
limited success. The ability to specifically target glioma cells can allow for the development of …

BTP-7, a novel peptide for therapeutic targeting of malignant brain tumors

N von Spreckelsen, Y Ghotmi, CM Fadzen, JM Wolfe… - bioRxiv, 2020 - biorxiv.org
Background Targeted therapies for malignant brain cancer that are currently available have
little clinical activity, highlighting an urgent need for the development of novel precision …

CHARACTERIZING THE CNS IMMUNE RESPONSE PROVOKED BY TWO GENETICALLY DIVERGENT STRAINS OF TOXOPLASMA GONDII

Y GHOTMI - 2016 - repository.arizona.edu
Toxoplasma gondii is an obligate intracellular parasite that infects a wide range of intermediate
hosts, including humans and rodents. For both humans and rodents, once infected …

DDIS-26. BTP-7, A NOVEL PEPTIDE FOR THERAPEUTIC TARGETING OF MALIGNANT BRAIN TUMORS

CF Cho, Y Ghotmi, C Fadzan, J Wolfe… - Neuro …, 2018 - ncbi.nlm.nih.gov
High-grade gliomas are deadly cancers, and current standard-of-care has demonstrated
limited success. The ability to specifically target glioma cells can allow for the development of …

Perfluoroarene–based peptide macrocycles to enhance penetration across the blood–brain barrier

CM Fadzen, JM Wolfe, CF Cho… - Journal of the …, 2017 - ACS Publications
… We also acknowledge Yarah Ghotmi for assistance in brain cryosections, Roscoe Wasserburg
for assistance with tissue culture, and Alex Mijalis for assistance in the synthesis of the …

[HTML][HTML] Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents

CF Cho, JM Wolfe, CM Fadzen, D Calligaris… - Nature …, 2017 - nature.com
Culture-based blood–brain barrier (BBB) models are crucial tools to enable rapid screening
of brain-penetrating drugs. However, reproducibility of in vitro barrier properties and …